Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy

Part of paid clinical trials in New York, New York.

Sponsor
Vitreous -Retina- Macula Consultants of New York
Study ID
NCT00403325
Phase
PHASE1
Status
Completed

Conditions

  • Central Serous Chorioretinopathy

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Accepted

Interventions

Study Details

The purpose of this study is to examine the effects of Lucentis for active Central Serous Chorioretinopathy.

Key Dates

First listed
Nov 23, 2006
Start date
Aug 31, 2006
Status verified
Oct 2008

Study Design

Enrollment
9 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

To determine the safety and tolerability of 0.5 mg dose of Ranibizumab in the treatment of chronic central serous retinopathy (CSC)

Locations (1)

FacilityCityStateZIPSite coordinators
Vitreous Retina Macula Consultants of New York, P.C.New YorkNew York10022-

Find similar trials in New York, NY

By research site
Vitreous Retina Macula Consultants of New York, P.C.· New York, NY

Related Studies